Neumora Therapeutics, Inc. is a leading clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on pioneering therapies for neuropsychiatric and neurodegenerative disorders. By harnessing innovative scientific methodologies, Neumora aims to tackle substantial unmet medical needs through its robust pipeline of novel compounds targeting essential biological pathways in complex brain diseases. With a commitment to developing transformative treatment options, the company is well-positioned to redefine care standards in neurology and significantly improve patient outcomes. Show more

Location: 490 ARSENAL WAY, WATERTOWN, MA, UNITED STATES, 02472, Watertown, MA, 02472, USA | Website: https://www.neumoratx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

333.1M

52 Wk Range

$0.61 - $3.25

Previous Close

$1.96

Open

$2.02

Volume

1,114,839

Day Range

$1.98 - $2.16

Enterprise Value

191.8M

Cash

129.1M

Avg Qtr Burn

-46.63M

Insider Ownership

26.83%

Institutional Own.

52.28%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Navacaprant (NMRA-140) Details Major depressive disorder, Mental health	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NMRA-511 Details Agitation in Alzheimer's Disease, Alzheimer's disease	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NMRA-898 Details Schizophrenia, neuropsychiatric disorders	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NMRA-861 Details Stable Schizophrenia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NMRA-266 Details Mental health, Schizophrenia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NMRA-215 (NLRP3 Inhibitor) Details Obesity	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Navacaprant (NMRA-140) Details Mental health, Bipolar depression	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.